Trade Recordati SPA - RECm CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Spread | 0.16 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.021388% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | -0.000834% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | EUR | ||||||||
Margin | 5% | ||||||||
Stock exchange | Italy | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Recordati Industria Chimica e Farmaceutica SpA ESG Risk Ratings
‘A’ score indicates excellent relative ESG performance and high degree of transparency in reporting material ESG data publicly
Prev. Close* | 45.04 |
Open* | 44.45 |
1-Year Change* | 14.41% |
Day's Range* | 44.45 - 45.6 |
52 wk Range | 34.52-47.34 |
Average Volume (10 days) | 285.08K |
Average Volume (3 months) | 5.07M |
Market Cap | 9.41B |
P/E Ratio | 23.94 |
Shares Outstanding | 205.54M |
Revenue | 2.01B |
EPS | 1.88 |
Dividend (Yield %) | 2.55499 |
Beta | 0.25 |
Next Earnings Date | Nov 7, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Sep 22, 2023 | 45.23 | 0.73 | 1.64% | 44.50 | 45.66 | 44.21 |
Sep 21, 2023 | 45.04 | -2.15 | -4.56% | 47.19 | 47.30 | 44.95 |
Sep 20, 2023 | 47.45 | 0.48 | 1.02% | 46.97 | 47.78 | 46.86 |
Sep 19, 2023 | 46.87 | 0.04 | 0.09% | 46.83 | 47.23 | 46.29 |
Sep 18, 2023 | 46.84 | 0.25 | 0.54% | 46.59 | 47.07 | 46.41 |
Sep 15, 2023 | 46.43 | -0.15 | -0.32% | 46.58 | 47.60 | 46.42 |
Sep 14, 2023 | 46.26 | 0.66 | 1.45% | 45.60 | 46.31 | 45.06 |
Sep 13, 2023 | 45.64 | 0.33 | 0.73% | 45.31 | 45.71 | 45.13 |
Sep 12, 2023 | 45.33 | 0.27 | 0.60% | 45.06 | 45.62 | 44.92 |
Sep 11, 2023 | 45.11 | -0.50 | -1.10% | 45.61 | 45.70 | 44.40 |
Sep 8, 2023 | 45.37 | 0.37 | 0.82% | 45.00 | 45.45 | 44.71 |
Sep 7, 2023 | 45.00 | 0.84 | 1.90% | 44.16 | 45.07 | 43.72 |
Sep 6, 2023 | 44.29 | -0.65 | -1.45% | 44.94 | 45.23 | 44.18 |
Sep 5, 2023 | 45.06 | -0.20 | -0.44% | 45.26 | 45.76 | 45.06 |
Sep 4, 2023 | 45.33 | -0.40 | -0.87% | 45.73 | 45.90 | 45.33 |
Sep 1, 2023 | 45.59 | -0.37 | -0.81% | 45.96 | 46.11 | 44.64 |
Aug 31, 2023 | 46.46 | 0.04 | 0.09% | 46.42 | 46.82 | 46.41 |
Aug 30, 2023 | 46.38 | -0.49 | -1.05% | 46.87 | 46.91 | 46.09 |
Aug 29, 2023 | 46.70 | 0.66 | 1.43% | 46.04 | 46.85 | 46.04 |
Aug 28, 2023 | 46.13 | 0.18 | 0.39% | 45.95 | 46.54 | 45.92 |
Recordati SPA Events
Time (UTC) | Country | Event |
---|---|---|
Tuesday, November 7, 2023 | ||
Time (UTC) 10:59 | Country IT
| Event Q3 2023 Recordati Industria Chimica e Farmaceutica SpA Earnings Release Q3 2023 Recordati Industria Chimica e Farmaceutica SpA Earnings ReleaseForecast -Previous - |
Monday, February 19, 2024 | ||
Time (UTC) 10:59 | Country IT
| Event Q4 2023 Recordati Industria Chimica e Farmaceutica SpA Earnings Release Q4 2023 Recordati Industria Chimica e Farmaceutica SpA Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total revenue | 1853.31 | 1580.07 | 1448.87 | 1481.85 | 1352.23 |
Revenue | 1853.31 | 1580.07 | 1448.87 | 1481.85 | 1352.23 |
Cost of Revenue, Total | 566.737 | 427.727 | 406.831 | 436.901 | 395.569 |
Gross Profit | 1286.57 | 1152.35 | 1042.04 | 1044.95 | 956.666 |
Total Operating Expense | 1411.47 | 1089.88 | 979.851 | 1016.58 | 910.016 |
Selling/General/Admin. Expenses, Total | 572.158 | 480.889 | 421.857 | 445.586 | 401.219 |
Research & Development | 220.102 | 166.138 | 146.236 | 77.081 | 67.093 |
Unusual Expense (Income) | 52.975 | 14.478 | 4.927 | 0.264 | 3.535 |
Operating Income | 441.832 | 490.19 | 469.016 | 465.266 | 442.219 |
Interest Income (Expense), Net Non-Operating | -40.252 | -26.718 | -13.203 | -20.616 | -17.977 |
Other, Net | -0.145 | -0.123 | -0.157 | -0.506 | -6.307 |
Net Income Before Taxes | 401.435 | 463.349 | 455.656 | 444.144 | 417.935 |
Net Income After Taxes | 312.336 | 385.966 | 355.027 | 368.866 | 312.422 |
Minority Interest | 0 | 0 | -0.043 | -0.041 | -0.046 |
Net Income Before Extra. Items | 312.336 | 385.966 | 354.984 | 368.825 | 312.376 |
Net Income | 312.336 | 385.966 | 354.984 | 368.825 | 312.376 |
Income Available to Common Excl. Extra. Items | 312.336 | 385.966 | 354.984 | 368.825 | 312.376 |
Income Available to Common Incl. Extra. Items | 312.336 | 385.966 | 354.984 | 368.825 | 312.376 |
Dilution Adjustment | |||||
Diluted Net Income | 312.336 | 385.966 | 354.984 | 368.825 | 312.376 |
Diluted Weighted Average Shares | 205.582 | 209.082 | 209.06 | 209.084 | 209.087 |
Diluted EPS Excluding Extraordinary Items | 1.51928 | 1.846 | 1.698 | 1.764 | 1.494 |
Dividends per Share - Common Stock Primary Issue | 1.15 | 1.1 | 1.05 | 1 | 0.92 |
Diluted Normalized EPS | 1.57912 | 1.89642 | 1.7131 | 1.76505 | 1.50664 |
Depreciation / Amortization | 52.6 | 42.6 | |||
Other Operating Expenses, Total | -0.497 | 0.652 | 0 | 4.15 |
Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
---|---|---|---|---|---|
Total revenue | 492.909 | 551.363 | 475.765 | 485.052 | 473.109 |
Revenue | 492.909 | 551.363 | 475.765 | 485.052 | 473.109 |
Cost of Revenue, Total | 148.3 | 163.654 | 143.933 | 154.924 | 152.402 |
Gross Profit | 344.609 | 387.709 | 331.832 | 330.128 | 320.707 |
Total Operating Expense | 351.991 | 377.95 | 384.224 | 362.353 | 376.788 |
Selling/General/Admin. Expenses, Total | 145.206 | 150.429 | 160.39 | 144.952 | 145.083 |
Research & Development | 58.585 | 60.458 | 64.402 | 56.367 | 55.664 |
Unusual Expense (Income) | 1.095 | 1.937 | 12.992 | 6.715 | 23.978 |
Other Operating Expenses, Total | -1.195 | 1.472 | 2.507 | -0.605 | -0.339 |
Operating Income | 140.918 | 173.413 | 91.541 | 122.699 | 96.321 |
Interest Income (Expense), Net Non-Operating | -11.898 | -13.38 | 0.239 | -7.103 | -26.462 |
Other, Net | -0.091 | -0.092 | -0.063 | -0.028 | -0.027 |
Net Income Before Taxes | 128.929 | 159.941 | 91.717 | 115.568 | 69.832 |
Net Income After Taxes | 103.617 | 123.954 | 70.878 | 90.053 | 54.685 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Net Income Before Extra. Items | 103.617 | 123.954 | 70.878 | 90.053 | 54.685 |
Net Income | 103.617 | 123.954 | 70.878 | 90.053 | 54.685 |
Income Available to Common Excl. Extra. Items | 103.617 | 123.954 | 70.878 | 90.053 | 54.685 |
Income Available to Common Incl. Extra. Items | 103.617 | 123.954 | 70.878 | 90.053 | 54.685 |
Diluted Net Income | 103.617 | 123.954 | 70.878 | 90.053 | 54.685 |
Diluted Weighted Average Shares | 205.421 | 209.029 | 205.417 | 205.602 | 208.895 |
Diluted EPS Excluding Extraordinary Items | 0.50441 | 0.593 | 0.34504 | 0.438 | 0.26178 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0.6 | 0 | 0.55 |
Diluted Normalized EPS | 0.55119 | 0.6427 | 0.36713 | 0.4423 | 0.29466 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Total Current Assets | 1173.62 | 850.101 | 772.951 | 809.35 | 699.931 |
Cash and Short Term Investments | 284.734 | 244.578 | 188.23 | 187.923 | 198.036 |
Cash | 162.636 | 230.924 | 175.227 | 141.384 | 172.421 |
Cash & Equivalents | 122.098 | 13.654 | 13.003 | 46.539 | 25.615 |
Total Receivables, Net | 424.062 | 350.335 | 313.859 | 374.328 | 281.276 |
Accounts Receivable - Trade, Net | 361.898 | 307.778 | 268.897 | 296.961 | 245.742 |
Total Inventory | 424.08 | 228.732 | 251.252 | 226.885 | 206.084 |
Prepaid Expenses | 17.138 | 15.307 | 12.574 | 10.265 | 8.121 |
Other Current Assets, Total | 23.603 | 11.149 | 7.036 | 9.949 | 6.414 |
Total Assets | 3998.82 | 2816.2 | 2711.65 | 2808.93 | 2161.26 |
Property/Plant/Equipment, Total - Net | 159.184 | 131.12 | 133.25 | 133.342 | 103.582 |
Property/Plant/Equipment, Total - Gross | 521.17 | 462.825 | 453.036 | 437.716 | 387.858 |
Accumulated Depreciation, Total | -361.986 | -331.705 | -319.786 | -304.374 | -284.276 |
Goodwill, Net | 780.057 | 553.209 | 562.116 | 577.973 | 577.786 |
Intangibles, Net | 1758.17 | 1138.79 | 1115.81 | 1161.76 | 672.106 |
Long Term Investments | 28.871 | 34.124 | 45.581 | 38.566 | 20.773 |
Other Long Term Assets, Total | 98.921 | 108.859 | 81.945 | 87.939 | 87.087 |
Total Current Liabilities | 923.743 | 626.416 | 578.464 | 586.754 | 490.742 |
Accounts Payable | 224.703 | 177.925 | 132.096 | 175.481 | 165.02 |
Accrued Expenses | 82.96 | 56.191 | 39.649 | 45.267 | 42.289 |
Notes Payable/Short Term Debt | 83.425 | 8.657 | 12.567 | 13.392 | 16.905 |
Current Port. of LT Debt/Capital Leases | 291.546 | 223.061 | 270.254 | 149.817 | 130.583 |
Other Current Liabilities, Total | 241.109 | 160.582 | 123.898 | 202.797 | 135.945 |
Total Liabilities | 2452.57 | 1434.57 | 1435.67 | 1610.35 | 1197.87 |
Total Long Term Debt | 1341.55 | 760.473 | 778.238 | 937.344 | 640.647 |
Long Term Debt | 1319.98 | 745.382 | 760.587 | 937.344 | 640.647 |
Deferred Income Tax | 167.865 | 26.675 | 41.219 | 43.172 | 43.486 |
Minority Interest | 0 | 0 | 0.277 | 0.234 | 0.193 |
Other Liabilities, Total | 19.418 | 21.01 | 37.473 | 42.849 | 22.804 |
Total Equity | 1546.25 | 1381.62 | 1275.98 | 1198.58 | 963.393 |
Common Stock | 26.141 | 26.141 | 26.141 | 26.141 | 26.141 |
Additional Paid-In Capital | 83.719 | 83.719 | 83.719 | 83.719 | 83.719 |
Retained Earnings (Accumulated Deficit) | 1785.72 | 1612.81 | 1473.6 | 1334.42 | 1161.69 |
Treasury Stock - Common | -149.559 | -126.981 | -87.516 | -93.48 | -145.608 |
Other Equity, Total | -199.769 | -214.06 | -219.962 | -152.223 | -162.545 |
Total Liabilities & Shareholders’ Equity | 3998.82 | 2816.2 | 2711.65 | 2808.93 | 2161.26 |
Total Common Shares Outstanding | 205.441 | 205.911 | 206.296 | 204.959 | 204.379 |
Capital Lease Obligations | 21.571 | 15.091 | 17.651 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 1191.21 | 1173.62 | 1242.55 | 1263.25 | 961.621 |
Cash and Short Term Investments | 231.294 | 284.734 | 346.609 | 373.762 | 261.43 |
Cash & Equivalents | 231.294 | 284.734 | 346.609 | 373.762 | 261.43 |
Total Receivables, Net | 488.17 | 425.813 | 443.062 | 440.645 | 407.68 |
Accounts Receivable - Trade, Net | 439.594 | 361.898 | 393.437 | 386.711 | 367.012 |
Total Inventory | 427.664 | 424.08 | 403.981 | 409.794 | 256.489 |
Other Current Assets, Total | 44.08 | 23.603 | 48.9 | 39.046 | 36.022 |
Total Assets | 3982.07 | 3998.82 | 3977.85 | 3984.1 | 3642.95 |
Property/Plant/Equipment, Total - Net | 162.311 | 159.184 | 147.226 | 143.839 | 129.207 |
Property/Plant/Equipment, Total - Gross | 528.919 | 521.17 | 504.681 | 495.512 | 464.469 |
Accumulated Depreciation, Total | -366.608 | -361.986 | -357.455 | -351.673 | -335.262 |
Goodwill, Net | 784.537 | 780.057 | 707.709 | 709.042 | 1125.12 |
Intangibles, Net | 1725.66 | 1758.17 | 1714.51 | 1711.72 | 1292.75 |
Long Term Investments | 24.48 | 28.871 | 26.972 | 19.57 | 23.34 |
Other Long Term Assets, Total | 93.88 | 98.921 | 138.884 | 136.683 | 110.922 |
Total Current Liabilities | 880.962 | 923.743 | 778.04 | 851.202 | 725.019 |
Accounts Payable | 246.983 | 224.703 | 219.638 | 222.533 | 194.998 |
Notes Payable/Short Term Debt | 23.232 | 83.425 | 5.656 | 74.279 | 15.022 |
Current Port. of LT Debt/Capital Leases | 293.631 | 291.546 | 290.496 | 303.406 | 252.279 |
Other Current Liabilities, Total | 317.116 | 324.069 | 262.25 | 250.984 | 262.72 |
Total Liabilities | 2327.6 | 2452.57 | 2367.38 | 2490.21 | 2193.52 |
Total Long Term Debt | 1263.98 | 1341.55 | 1404.18 | 1450.22 | 1403.58 |
Long Term Debt | 1241.75 | 1319.98 | 1389.79 | 1435 | 1389.77 |
Deferred Income Tax | 163.737 | 167.865 | 163.776 | 167.462 | 26.909 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 18.924 | 19.418 | 21.39 | 21.33 | 38.015 |
Total Equity | 1654.47 | 1546.25 | 1610.47 | 1493.89 | 1449.43 |
Common Stock | 26.141 | 26.141 | 26.141 | 26.141 | 26.141 |
Additional Paid-In Capital | 83.719 | 83.719 | 83.719 | 83.719 | 83.719 |
Retained Earnings (Accumulated Deficit) | 1920.3 | 1785.72 | 1761.87 | 1663.8 | 1699.78 |
Treasury Stock - Common | -152.695 | -149.559 | -149.782 | -141.16 | -144.381 |
Other Equity, Total | -222.995 | -199.769 | -111.476 | -138.613 | -215.826 |
Total Liabilities & Shareholders’ Equity | 3982.07 | 3998.82 | 3977.85 | 3984.1 | 3642.95 |
Total Common Shares Outstanding | 205.358 | 205.441 | 205.459 | 205.665 | 205.587 |
Prepaid Expenses | 15.387 | ||||
Capital Lease Obligations | 22.233 | 21.571 | 14.387 | 15.219 | 13.81 |
- Annual
- Quarterly
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Net income/Starting Line | 312.336 | 385.966 | 355.027 | 368.866 | 312.422 |
Cash From Operating Activities | 461.691 | 492.129 | 403.575 | 318.7 | 357.838 |
Cash From Operating Activities | 27.289 | 25.294 | 25.355 | 25.17 | 13.901 |
Amortization | 98.467 | 72.291 | 68.317 | 53.078 | 42.959 |
Deferred Taxes | -6.637 | ||||
Non-Cash Items | 209.716 | 113.194 | 124.979 | 102.747 | 4.697 |
Changes in Working Capital | -186.117 | -104.616 | -170.103 | -231.161 | -9.504 |
Cash From Investing Activities | -767.124 | -87.499 | -131.555 | -441.209 | -231.778 |
Capital Expenditures | -96.339 | -87.36 | -131.678 | -443.288 | -19.362 |
Other Investing Cash Flow Items, Total | -670.785 | -0.139 | 0.123 | 2.079 | -212.416 |
Cash From Financing Activities | 341.277 | -355.943 | -264.288 | 109.526 | -224.688 |
Financing Cash Flow Items | 1.74 | -2.19 | 0.439 | ||
Total Cash Dividends Paid | -230.602 | -216.742 | -212.718 | -190.916 | -178.887 |
Issuance (Retirement) of Stock, Net | -38.619 | -59.308 | -12.17 | 26.187 | -149.552 |
Issuance (Retirement) of Debt, Net | 610.498 | -79.893 | -41.14 | 276.445 | 103.312 |
Net Change in Cash | 40.156 | 56.348 | 0.307 | -10.113 | -104.369 |
Foreign Exchange Effects | 4.312 | 7.661 | -7.425 | 2.87 | -5.741 |
Cash Taxes Paid | 89.764 | 91.646 | 65.272 | 140.14 | |
Cash Interest Paid | 20.093 | 18.279 | 18.699 | 17.597 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 123.954 | 312.336 | 241.458 | 151.405 | 96.72 |
Cash From Operating Activities | 107.923 | 461.691 | 361.692 | 226.113 | 113.431 |
Cash From Operating Activities | 7.004 | 27.289 | 19.675 | 12.895 | 6.016 |
Amortization | 27.188 | 98.467 | 70.563 | 44.289 | 18.635 |
Non-Cash Items | 66.727 | 209.716 | 145.296 | 97.032 | 35.714 |
Cash Taxes Paid | 12.33 | 89.764 | 55.992 | 42.515 | 10.653 |
Cash Interest Paid | 17.818 | 20.093 | 14.385 | 8.569 | 2.344 |
Changes in Working Capital | -116.95 | -186.117 | -115.3 | -79.508 | -43.654 |
Cash From Investing Activities | -14.006 | -767.124 | -736.385 | -715.11 | -722.27 |
Capital Expenditures | -17.557 | -96.339 | -83.684 | -62.222 | -15.599 |
Other Investing Cash Flow Items, Total | 3.551 | -670.785 | -652.701 | -652.888 | -706.671 |
Cash From Financing Activities | -144.562 | 341.277 | 452.436 | 601.573 | 571.438 |
Total Cash Dividends Paid | -6.139 | -230.602 | -120.017 | -119.544 | -6.219 |
Issuance (Retirement) of Stock, Net | -4.075 | -38.619 | -29.989 | -16.634 | -18.383 |
Issuance (Retirement) of Debt, Net | -134.348 | 610.498 | 602.442 | 737.751 | 596.04 |
Foreign Exchange Effects | -2.795 | 4.312 | 24.288 | 16.608 | 1.018 |
Net Change in Cash | -53.44 | 40.156 | 102.031 | 129.184 | -36.383 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
Fimei Finanziaria Industriale Mobiliare Ed Immobiliare SpA | Holding Company | 51.82 | 108368656 | 0 | 2022-12-31 | LOW |
Mawer Investment Management Ltd. | Investment Advisor | 4.997 | 10449984 | -43916 | 2022-12-07 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 3.402 | 7114438 | 0 | 2022-12-31 | LOW |
FMR Investment Management (U.K.) Limited | Investment Advisor | 1.7394 | 3637578 | -12900 | 2023-06-30 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 1.4165 | 2962262 | 25699 | 2023-07-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.2673 | 2650202 | 14183 | 2023-07-31 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.968 | 2024252 | 293858 | 2022-12-31 | LOW |
La Financière de l'Echiquier | Investment Advisor | 0.6879 | 1438565 | -63157 | 2023-05-31 | MED |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5654 | 1182440 | 718 | 2023-07-31 | LOW |
BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 0.4835 | 1011020 | 22229 | 2023-07-31 | LOW |
Manulife Investment Management (North America) Limited | Investment Advisor | 0.4779 | 999364 | 1609 | 2023-06-30 | LOW |
Amundi Asset Management, SAS | Investment Advisor/Hedge Fund | 0.4384 | 916749 | -1663 | 2023-07-31 | LOW |
INVESCO Asset Management Limited | Investment Advisor/Hedge Fund | 0.4198 | 877833 | 12866 | 2023-06-30 | LOW |
Invesco Advisers, Inc. | Investment Advisor | 0.3717 | 777303 | 69272 | 2023-06-30 | LOW |
California Public Employees' Retirement System | Pension Fund | 0.3634 | 759886 | -15901 | 2022-06-30 | LOW |
Schroder Investment Management Ltd. (SIM) | Investment Advisor/Hedge Fund | 0.3562 | 744985 | 0 | 2023-06-30 | LOW |
Walter Scott & Partners Ltd. | Investment Advisor/Hedge Fund | 0.3371 | 705012 | -1664 | 2023-06-30 | LOW |
TD Asset Management Inc. | Investment Advisor | 0.3182 | 665492 | 1359 | 2023-07-31 | LOW |
Epoch Investment Partners, Inc. | Investment Advisor | 0.3134 | 655311 | 898 | 2023-07-31 | LOW |
Anima SGR S.p.A. | Investment Advisor | 0.2878 | 601954 | 65096 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Recordati Company profile
About Recordati Industria Chimica e Farma SpA
Recordati Industria Chimica e Farmaceutica SpA is an Italy-based group engaged in the research, development, manufacture and marketing of pharmaceuticals. It promotes a wide range of pharmaceuticals, both proprietary and under license, in a number of therapeutic areas, such as Antibiotics and Antiviral, Cardiovascular, Central nervous system, Dermatological, Gastroenterology, Genital-urinary system, Muscular-skeletal disorders and pain therapy, Obstetrics and Gynecology and over the counter (OTC) pharmaceuticals. The Company is engaged in the research and development of new drug entities within the cardiovascular and urogenital therapeutic areas and of treatments for rare diseases. It’s product is ZANIDIP, a latest generation calcium-channel blocker for the treatment hypertension. It operates through Italchimici SpA, Pro Farma AG and North American marketing rights to Cystadane. The Company owns and operates through Natural Point srl also in the food supplement sector.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Recordati Industria Chimica e Farma SpA revenues increased 9% to EUR1.58B. Net income increased 9% to EUR386M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Dividend per share increased from EUR1.05 to EUR1.10. Basic Earnings per Share excluding Extraordinary Items increased from EUR1.73 to EUR1.87.
Industry: | Pharmaceuticals (NEC) |
Via M. Civitali, 1
MILANO
MILANO 20148
IT
Income Statement
- Annual
- Quarterly
News

EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com